The short version of GLP-1 receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-07 and is reviewed periodically as new material appears.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
=== Clinical trials === PL9643, an ophthalmic solution, is being tested in phase 3 clinical trials to determine safety and efficacy in patients with dry eye. PL9643 activates MC1R, MC3R, MC4R and MC5R. Completed Phase 2 studies demonstrated positive results for the treatment of dry eye disease. Dersimelagon (MT-7117) is an orally administered MC1R agonist being tested in phase 3 clinical trials to evaluate safety and tolerability in patients with erythropoietic protoporphyria or X-linked protoporphyria. Resomelagon (AP1189) is an orally administered MC1R and MC3R agonist being tested in three phase 2 clinical trials to study safety and efficacy in patients with rheumatoid arthritis and idiopathic membranous nephropathy.
Trump formally notified the United States Congress on 1 October 2025 that the US was in a "non-international armed conflict" with "unlawful combatants" regarding drug cartels in the Caribbean, specifically referencing the 15 September strike. The Miami Herald wrote that: "In an armed conflict, a country can lawfully kill enemy fighters even when they pose no threat." Initially positioned as a mission to stop narcotics traffic to the US, by mid-October, Venezuelan opposition figures and independent analysts stated the American objective had shifted to regime change, with Trump acknowledging the possibility of strikes within Venezuelan territory. On 16 October, Admiral Alvin Holsey, the commander of United States Southern Command, announced that he would retire at the end of the year, less than a year into what is normally a three-year placement, with anonymous sources reporting tension between Holsey and the Trump administration over Venezuela. Two unnamed officials told The Wall Street Journal that tension between Hegseth and Holsey began early during Trump's administration over military planning involving the Panama Canal, with Hegseth wanting to replace Holsey, but differences intensified when "Holsey was initially concerned about murky legal authority for the boat strike campaign" and "objected that parts of the operations fell outside his direct control". The sources stated that, after months of tension, there was a confrontational meeting in October, and Holsey's resignation was announced the same day.
== History == In 1891 G. Merling obtained a water-soluble bromine-containing compound from the reaction of cycloheptatriene and bromine. Unlike most alkyl bromides, this compound, later named tropylium bromide, is water-soluble but insoluble in many organic solvents. It is purified by crystallization from hot ethanol. Reaction with aqueous silver nitrate immediately gave silver bromide, indicating labile bromide. Tropylium bromide was deduced to be a salt, C7H+7Br−, by Doering and Knox in 1954 by analysis of its infrared and ultraviolet spectra. The ionic structures of tropylium perchlorate (C7H+7ClO−4) and tropylium iodide (C7H+7I−) have been confirmed by X-ray crystallography. The bond length of the carbon-carbon bonds is longer (147 pm) than those of benzene (140 pm) but still shorter than those of a typical single-bonded species like ethane (154 pm).
The Berlin Crisis of 1961 was the last major incident in the Cold War regarding the status of Berlin and post–World War II Germany. By the early 1950s, the Soviet approach to restricting emigration movement was emulated by most of the rest of the Eastern Bloc. However, hundreds of thousands of East Germans annually emigrated to free and prosperous West Germany through a "loophole" in the system that existed between East Berlin and West Berlin. The emigration resulted in a massive "brain drain" from East Germany to West Germany of younger educated professionals, such that nearly 20% of East Germany's population had migrated to West Germany by 1961. That June, the Soviet Union issued a new ultimatum demanding the withdrawal of Allied forces from West Berlin. The request was rebuffed, but the United States now limited its security guarantees to West Berlin. On 13 August, East Germany erected a barbed-wire barrier that would eventually be expanded through construction into the Berlin Wall, effectively closing the loophole and preventing its citizens from fleeing to the West.
Sources: en.wikipedia.org
The Trump administration blamed Congress for the atrocity and labelled the change in policy as "the Democrats' law", even though Congress had been overwhelmingly dominated by Republicans since 2016. Regardless, members of both parties criticised the policy, and detractors of the Trump administration emphasise that there does not seem to be any written law requiring the government to implement such a policy. Attorney General Jeff Sessions, in defending the policy, quoted a passage from the Bible, even though religious doctrine carries absolutely no weight in American law. Other officials praised the policy as a deterrent to unlawful immigration. The costs of separating migrant children from their parents and keeping them in "tent cities" are higher than keeping them with their parents in detention centres. To handle the large amount of immigration charges brought by the Trump administration, federal prosecutors had to divert resources from other crime cases. It costs $775 per person per night to house the children when they are separated but $256 per person per night when they are held in permanent HHS facilities and $298 per person per night to keep the children with their parents in immigration detention centres. The head of the Justice Department's major crimes unit in San Diego diverted staff from drug smuggling cases. Drug smuggling cases were also increasingly pursued in state courts rather than federal courts, as federal prosecutors were increasingly preoccupied with pursuing charges against illegal border crossings.
Some say we should hold elections tomorrow, those have no chances of being free and fair." and added "Ultimately what the long term political leadership is going be, it’s going to be up to Venezuelans." During a conference in Saint Kitts and Nevis with other Caribbean nations on 25 February, United States Secretary of State Marco Rubio said that the US recognizes the need for fair, democratic elections in Venezuela, saying "We do believe that a prosperous, free Venezuela who’s governed by a legitimate government who has the interests of their people in mind could also be an extraordinary partner and asset to many of the countries represented here today." Juan Pablo Guanipa, ally of Machado and political prisoner released during a mass political prisoner release in Venezuela in 2026, said for Spanish newspaper El País, that elections are under way and that Chavismo has lost its ability to impose conditions.
=== Worms === Levamisole was originally used as an anthelmintic to treat worm infestations in both humans and animals. Levamisole works as a nicotinic acetylcholine receptor agonist that causes continued stimulation of the parasitic worm muscles, leading to paralysis. Levamisole has gained prominence among aquarists as an effective treatment for Camallanus roundworm infestations in freshwater tropical fish. Levamisole has been used to treat small ruminant animals since the late 1960s. Levamisole-resistant parasitic worms are common in sheep farms in New Zealand, Uruguay, Paraguay, and Brazil.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.